The successful development of a recombinant E2 subunit vaccine against CSFV represents a strategic advance toward sustainable control and eventual eradication of the disease.
Abstract
CSFV is a highly contagious disease threatening global pig production. Conventional live vaccines protect effectively but prevent serological differentiation between infected and vaccinated animals-undermining surveillance and eradication efforts. Therefore, it is crucial to develop a new generation of safe and effective vaccines. This study targeted the CSFV E2 glycoprotein, rationally optimized its amino acid sequence, expressed the recombinant protein at high yield in CHO cells, and demonstrated its immunogenicity and complete protection against virulent CSFV challenge. The E2 subunit vaccine was safe in piglets, with no inflammation, fever, or mortality during immunization. The E2 subunit vaccine induces high titers of CSFV-specific and neutralizing antibodies, and its immune protection efficacy is no less than that of commercially available vaccines. In the piglet challenge test, no CSFV was detected in oral, nasal, or rectal swabs or peripheral blood from immunized piglets. No CSFV was detected in the spleen, lymph nodes, or tonsils at autopsy. No CSFV-specific lesions were found on histopathology. All immunized piglets survived. These results demonstrate that piglets vaccinated with the E2 subunit vaccine were completely protected against lethal CSFV challenge. The successful development of a recombinant E2 subunit vaccine against CSFV represents a strategic advance toward sustainable control and eventual eradication of the disease.
Immunization with adenovirus serotype 5 (AdV5) vectors expressing CCHFV antigens elicited potent humoral and cellular immune responses, conferring 100% protection against lethal viral challenge across the majority of evaluated formulations.
A. Hanifehnezhad, S. Oztop, E. Tavukçuoğlu et al.· Scientific Reports· 1 citation
It is demonstrated that needle-free delivery of rPRVTJ-UL44-E2 confers complete protection against lethal CSFV challenge in pigs via needle-free immunization.
Ruojia Huang, Qiang Yang, Cao-Yuan Ma et al.· Vaccines· 0 citations
Background Infection of susceptible livestock species, including domestic cattle and American bison, with ovine gammaherpesvirus-2 (OvHV-2), a gammaherpesvirus in the genus Macavirus, can result in an often-fatal disease known as sheep-associated malignant catarrhal fever (SA-MCF). Prevention of SA-MCF via vaccination...
Daniela D. Moré, N. Taus, Katherine N. Baker et al.· Frontiers in Immunology· 0 citations
PEDV-MS2 VLPs demonstrate excellent safety and are a novel candidate vaccine for porcine epidemic diarrhea virus, a significant threat to the global swine industry.
Ya-Wen Liu, Si-Ying Du, Shan Xu et al.· European journal of pharmace...· 0 citations
Two recombinant chimpanzee adenovirus vaccine candidates were constructed to express the GP35 or M-GP5 fusion proteins of the PRRSV NADC30-like strain, resulting in a potent antigen-specific immune response, including enhanced GP5-specific antibody production, neutralizing activity, and T-cell-mediated immunity.
Chi Liu, Peng Ma, Jian-Lan Li et al.· Vaccine· 0 citations
Results indicate that S1–F-VLP confers robust immune protection against the highly virulent PEDV strain and holds promise as a clinical candidate vaccine.
Zhiqiang Li, Jie Li, Jiahai Cheng et al.· Biochemistry and Biophysics...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.